Feature | April 18, 2007 | Cristen C. Bolan

WEB EXCLUSIVE: Quantification Pushes Nuclear Medicine Bedside

2006 - 2007 SNM President Martin P. Sandler, M.D., Vanderbilt University Medical Center, Department of Radiology and Radiological Sciences

“I think quantification is the next big breakthrough in imaging technology,” said the 2006 – 2007 SNM President Martin P. Sandler, M.D., of Vanderbilt University Medical Center, Department of Radiology and Radiological Sciences, in an interview with Imaging Technology News (ITN) on the future of nuclear medicine.
The Society of Nuclear Medicine (SNM) has embarked on a mission to improve healthcare by advancing molecular imaging and therapy, and the SNM 2007 conference program will feature an increased presence of related research. ITN talked to Dr. Sandler about how nuclear medicine will drive personalized medicine in the future.

ITN: How is molecular imaging using imaging technology such as PET, SPECT, MRI and others to develop personalized medicine?

Martin P. Sandler, M.D. (MS): It is the understanding of how cellular function and biological processes of the cell work from the receptor through the cell membrane all the way to the inner functions of the cell. By looking at different receptor sites and different activities of the cell one can develop specific imaging and therapeutic interventions that will be tailored for individuals based on the ability of the receptors to respond to specific probes as well as certain therapeutic interventions.

ITN: How has molecular imaging and nuclear medicine research led to improvements in the diagnosis and treatment of cancer, heart disease and brain disorders?
MS: It has the potential to affect a large variety of diseases, including cardiac disease, and various cancers. We have already seen it with monoclonal antibodies and there is the possibility of that certain brain disorders have the potential to be responsive, as well. It covers a host of different diseases.

ITN: Can you describe what the new program InfoSNM involves and what the objective is?
MS: We have developed a number of live, interactive lifelong learning programs and people can access the educational component and with that is a continuing medical education component that goes along with these. These are live, interactive programs. There is also training of clinicians and technologists with hybrid imaging, which is a key part of the molecular imaging process or where by you have a congruence of different technologies giving different synergistic kinds of information.

ITN: Exactly which hybrids are you referring to?
MS: These hybrids include PET/CT, SPECT/CT and also work being done on PET/MRI.
Simon Cherry, who gave the Henry Wagner lecture at last year’s SNM, showed that scientists have overcome the technical challenges of integrating PET and MRI imaging. There are models now that are being worked on now.
PET/MRI has the advantage s there is of less radiation and MR gives different kinds of information, such as MR spectroscopy’s the ability to overlap MR spectroscopy on a tumor and look at its therapeutic response. All of the different roles of MR versus CT can now be combined potentially with PET, as can CT.

ITN: What are some of the advancements you anticipate will develop in Nuclear Medicine over the next five years?
MS: Besides the translational development of new products and nanoparticle technology, I think that the biggest advancement will be bringing quantitative measurements to the bedside. If you look at cardiac imaging today, we are looking at relative blood flow. We steal blood from parts of the heart that have narrowing of blood vessels and look at compare it to other parts of the heart with normal blood flow. With pharmacological exercises we improve blood flow, we increase blood flow and we look at relative diminishment in blood flow. I think that we are soon going to have technologies, which have high enough contrast count rates and resolution such that we will have the same sensitivity for gamma camera imaging as we do with PET. This will allow us to quantitate absolute blood flow and the ml/min diminish for 100 grams of tissue. I think quantification is the next big breakthrough in imaging technology.

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init